Advanced Filters
noise

Lung Disease Clinical Trials

A listing of Lung Disease medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 3,178 clinical trials

Evaluation of High Dose Prednisolone Pharmacokinetics in the Acute and Chronic Setting

This is a pilot study to investigate serum prednisolone profiles in: Patients on high doses of prednisolone for any inflammatory disorder, both in the acute and chronic setting. Patients stepping up from or down to prednisolone therapy in association with a course of high dose methyl-prednisolone or dexamethasone. The study …

18 - 75 years of age All Phase N/A
D Donglai Lv, MD

CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors

This study is a single-arm, open-label, dose-escalating + dose-expansion clinical study, aiming to evaluate the safety and efficacy of CEA-targeted CAR-T cell preparations, and to preliminarily observe the study drug in CEA-positive advanced malignant tumors. The pharmacokinetic characteristics of CAR-T cell preparations for the treatment of patients with CEA-positive advanced …

18 years of age All Phase 1
J Jianyang Wang, MD

SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC

This phase III trial compares the effect of stereotactic radiosurgery and whole brain radiation therapy that avoids the hippocampus (the memory zone of the brain) for the treatment of small cell lung cancer that has spread to the brain.

18 - 80 years of age All Phase 3
L LIliana Gutierrez, RN, MSc

Vortioxetine for Cognitive Function in ALK-positive NSCLC Treated With Lorlatinib

This observational study evaluates whether vortioxetine - an antidepressant medication with cognitive-enhancing properties - can reduce the neurological and cognitive side effects associated with lorlatinib treatment in patients with non-small cell lung cancer (NSCLC) harboring ALK or ROS1 gene rearrangements. Lorlatinib is a highly effective third-generation tyrosine kinase inhibitor, but …

18 years of age All Phase N/A
S Site Public Contact

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: Does CP-383 slow or stop the growth of cancer in patients with advanced cancer …

18 years of age All Phase 1/2
E Elisabeth M Schneider, PhD

Immune Modulation by Exosomes in COVID-19

Following whole blood stimulation with mesenchymal stem cell derived exosomes, immune phenotype, cytokine release and mRNA expression patterns from critically ill patients with COVID-19 will be determined.

18 - 90 years of age All Phase N/A
C Costantine Albany, MD

A Study Evaluating the Safety and Efficacy of HB0036 in Subjects With Advanced Solid Tumors

It is a Phase I/II, Open-label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of HB0036 in Subjects with Advanced Solid Tumors

18 years of age All Phase 1/2

Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients

A Phase 1b/2, open-label, multicenter study to determine the recommended phase 2 (RP2D) of ABT-101in solid tumor and to explore antitumor activities of ABT-101 in patients with HER 2 mutated non-small cell lung cancer (NSCLC)

18 years of age All Phase 1/2

A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.

The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.

18 years of age All Phase 1
C Caicun Zhou, PhD

A Study of XZB-0004 in Patients With Solid Tumors

XZB-0004 is a novel and potent small molecule inhibitor of receptor tyrosine kinase AXL. This is an open-label, multicentre phase I study of XZB-0004 in patients with solid tumors. Part 1 is a dose-escalation study to evaluate the safety, pharmacokinetic (PK), and pharmacodynamic profile of XZB-0004, and then to identify …

18 - 75 years of age All Phase 1

Simplify language using AI